Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT06676527 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT06676527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06676527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Lead sponsor
Jinling Hospital, China
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2024
Completion date
September 1, 2026
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, carcinoma, carcinoma, renal cell, female urogenital diseases, kidney diseases, kidney neoplasms, male urogenital diseases, neoplasms, renal cell cancer, urogenital diseases, urogenital neoplasms, urologic diseases, urologic neoplasms